


PHARMACEUTICAL 2020



Akebia Therapeutics Inc. Rank 150 of 362





PHARMACEUTICAL 2020

Akebia

Akebia Therapeutics Inc. Rank 150 of 362

The relative strengths and weaknesses of Akebia Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Akebia Therapeutics Inc. compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 151% points. The greatest weakness of Akebia Therapeutics Inc. is the variable Assets, Current, reducing the Economic Capital Ratio by 96% points.

The company's Economic Capital Ratio, given in the ranking table, is -122%, being 181% points above the market average of -303%.

Input Variable	Value in 1000 USD
Assets, Current	309,533
Cost of Goods Sold	145,336
Intangible Assets	55,053
Liabilities, Current	208,118
Liabilities, Non-Current	166,676
Other Assets	396,235
Other Compr. Net Income	261
Other Expenses	-3,102
Other Liabilities	1,650
Other Net Income	-2.0
Property and Equipment	10,380
Research and Development	322,969
Revenues	335,001
Selling, General and Administrative Expense	149,455

Output Variable	Value in 1000 USD
Assets	771,201
Liabilities	376,444
Expenses	614,658
Stockholders Equity	394,757
Net Income	-279,659
Comprehensive Net Income	-279,528
Economic Capital Ratio	-122%